UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Diminishing Marginal Disutility of Hypoglycaemic Events

Value in health, 2013-11, Vol.16 (7), p.A445-A445

2013

Volltextzugriff (PDF)

Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine in a Basal-Bolus Regimen in Patients with Type 1 Diabetes Mellitus in the United Kingdom

Value in health, 2013-11, Vol.16 (7), p.A442-A442

2013

Volltextzugriff (PDF)

Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine for Patients with Type 2 Diabetes Mellitus Initiating Insulin Therapy in the United Kingdom

Value in health, 2013-11, Vol.16 (7), p.A442-A442

2013

Volltextzugriff (PDF)

Benchmarks for interpretation of score differences on the SF-36 health survey

Value in health, 2013-05, Vol.16 (3), p.A35-A35

2013

Volltextzugriff (PDF)

PDB19 A Systematic Review of Recent Data Describing the Risk of Complications in Type 1 Diabetes Mellitus Patients

Value in health, 2012-11, Vol.15 (7), p.A496-A497

2012

Volltextzugriff (PDF)

PDB60 COST-EFFECTIVENESS OF INSULIN DEGLUDEC VERSUS INSULIN GLARGINE U300 IN THE NETHERLANDS: EVIDENCE FROM A RANDOMISED CONTROLLED TRIAL (RCT)

Value in health, 2019-11, Vol.22, p.S583-S583

2019

Volltextzugriff (PDF)

Cost-Effectiveness of Switching To Insulin Degludec (IDEG) In Real-World Clinical Practice In Italy

Value in health, 2017-10, Vol.20 (9), p.A478-A479

2017

Volltextzugriff (PDF)

PDB27 - Cost-Effectiveness of Switching To Insulin Degludec (IDEG) In Real-World Clinical Practice In Italy

Value in health, 2017-10, Vol.20 (9), p.A478-A479

2017

Volltextzugriff (PDF)

PDB48 - Annual Cost and Effects of Switching to Insulin Degludec from Other Basal Insulins: Evidence from Swedish Real-World Data

Value in health, 2016-11, Vol.19 (7), p.A673-A673

2016

Volltextzugriff (PDF)

Annual Cost and Effects of Switching to Insulin Degludec from Other Basal Insulins: Evidence from Swedish Real-World Data

Value in health, 2016-11, Vol.19 (7), p.A673-A673

2016

Volltextzugriff (PDF)

Cost-Effectiveness of Insulin Degludec/Insulin Aspart (IDEGASP) Compared with Biphasic Insulin Aspart (BIASP 30) in Patients with Type 2 Diabetes Mellitus from a Mexican Healthcare Perspective

Value in health, 2016-11, Vol.19 (7), p.A672-A672

2016

Volltextzugriff (PDF)

PDB43 - Cost-Effectiveness of Insulin Degludec/Insulin Aspart (IDEGASP) Compared with Biphasic Insulin Aspart (BIASP 30) in Patients with Type 2 Diabetes Mellitus from a Mexican Healthcare Perspective

Value in health, 2016-11, Vol.19 (7), p.A672-A672

2016

Volltextzugriff (PDF)

PDB81 - Diminishing Marginal Disutility of Hypoglycaemic Events

Value in health, 2013-11, Vol.16 (7), p.A445-A445

2013

Volltextzugriff (PDF)

PDB65 - Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine for Patients with Type 2 Diabetes Mellitus Initiating Insulin Therapy in the United Kingdom

Value in health, 2013-11, Vol.16 (7), p.A442-A442

2013

Volltextzugriff (PDF)

PDB64 - Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine in a Basal-Bolus Regimen in Patients with Type 1 Diabetes Mellitus in the United Kingdom

Value in health, 2013-11, Vol.16 (7), p.A442-A442

2013

Volltextzugriff (PDF)

PRM126 - Benchmarks for interpretation of score differences on the SF-36 health survey

Value in health, 2013-05, Vol.16 (3), p.A35-A35

2013

Volltextzugriff (PDF)

Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspective

Patient preference and adherence, 2013-01, Vol.7 (default), p.925-936

2013

Volltextzugriff (PDF)

PDB17 THE HEALTH CARE COSTS OF LONG-ACTING INSULIN ANALOGS COMPARED WITH NPH INSULIN IN PATIENTS WITH TYPE 2 DIABETES USING A BASAL REGIMEN: A DANISH PERSPECTIVE

Value in health, 2010, Vol.13 (3), p.A57-A57

2010

Volltextzugriff (PDF)

PHP11 DOSE DISPENSED MEDICINE AND ASSOCIATED MEDICINE AND HEALTH CARE COST

Value in health, 2006-11, Vol.9 (6), p.A211-A211

2006

Volltextzugriff (PDF)

Smart Insulin Pens are Associated with Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type 1 Diabetes in Sweden: A Cost-Effectiveness Analysis

Diabetes therapy, 2021-01, Vol.12 (1), p.373-388

2021

Volltextzugriff (PDF)

DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal–Bolus Regimens for Type 2 Diabetes in the UK

Diabetes therapy, 2018-06, Vol.9 (3), p.1217-1232

2018

Volltextzugriff (PDF)

The Danish Testicular Cancer database

Clinical epidemiology, 2016-01, Vol.8, p.703-707

2016

Volltextzugriff (PDF)

Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective

Journal of medical economics, 2020-11, Vol.23 (11), p.1311-1320

2020

Volltextzugriff (PDF)

Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)

Applied health economics and health policy, 2019-10, Vol.17 (5), p.615-627

2019

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(24)

Sprache

Englisch
(24)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Value In Health
(18)
Diabetes Therapy
(2)
Applied Health Economics And Health Policy
(1)
Clinical Epidemiology
(1)
Journal Of Medical Economics
(1)
Patient Preference And Adherence
(1)

1 weiteren anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Diminishing Marginal Disutility of Hypoglycaemic Events

Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine in a Basal-Bolus Regimen in Patients with Type 1 Diabetes Mellitus in the United Kingdom

Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine for Patients with Type 2 Diabetes Mellitus Initiating Insulin Therapy in the United Kingdom

Benchmarks for interpretation of score differences on the SF-36 health survey

PDB19 A Systematic Review of Recent Data Describing the Risk of Complications in Type 1 Diabetes Mellitus Patients

PDB60 COST-EFFECTIVENESS OF INSULIN DEGLUDEC VERSUS INSULIN GLARGINE U300 IN THE NETHERLANDS: EVIDENCE FROM A RANDOMISED CONTROLLED TRIAL (RCT)

Cost-Effectiveness of Switching To Insulin Degludec (IDEG) In Real-World Clinical Practice In Italy

PDB27 - Cost-Effectiveness of Switching To Insulin Degludec (IDEG) In Real-World Clinical Practice In Italy

PDB48 - Annual Cost and Effects of Switching to Insulin Degludec from Other Basal Insulins: Evidence from Swedish Real-World Data

Annual Cost and Effects of Switching to Insulin Degludec from Other Basal Insulins: Evidence from Swedish Real-World Data

Cost-Effectiveness of Insulin Degludec/Insulin Aspart (IDEGASP) Compared with Biphasic Insulin Aspart (BIASP 30) in Patients with Type 2 Diabetes Mellitus from a Mexican Healthcare Perspective

PDB43 - Cost-Effectiveness of Insulin Degludec/Insulin Aspart (IDEGASP) Compared with Biphasic Insulin Aspart (BIASP 30) in Patients with Type 2 Diabetes Mellitus from a Mexican Healthcare Perspective

PDB81 - Diminishing Marginal Disutility of Hypoglycaemic Events

PDB65 - Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine for Patients with Type 2 Diabetes Mellitus Initiating Insulin Therapy in the United Kingdom

PDB64 - Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine in a Basal-Bolus Regimen in Patients with Type 1 Diabetes Mellitus in the United Kingdom

PRM126 - Benchmarks for interpretation of score differences on the SF-36 health survey

Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspective

PDB17 THE HEALTH CARE COSTS OF LONG-ACTING INSULIN ANALOGS COMPARED WITH NPH INSULIN IN PATIENTS WITH TYPE 2 DIABETES USING A BASAL REGIMEN: A DANISH PERSPECTIVE

PHP11 DOSE DISPENSED MEDICINE AND ASSOCIATED MEDICINE AND HEALTH CARE COST

Smart Insulin Pens are Associated with Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type 1 Diabetes in Sweden: A Cost-Effectiveness Analysis

DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal–Bolus Regimens for Type 2 Diabetes in the UK

The Danish Testicular Cancer database

Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective

Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)

Aktive Filter

Suchergebnisse filtern